ArticleHereditas2025
Clinical significance of LINC01158 in breast cancer and inhibition of proliferation and metastasis of breast cancer cells by regulating miR-711.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveBreast cancer (BC) has a poor prognosis due to metastasis and recurrence. LINC01158 is aberrantly expressed in breast cancer. Therefore, we investigated the regulatory mechanism and prognostic value of LINC01158 in BC.
methods121 patients with BC were enrolled. LINC01158 and miR-711 levels were analyzed by RT-qPCR. Independent predictors of poor BC prognosis were analyzed by multifactorial Cox regression. Kaplan-Meier curves were used to analyze the 5-year survival rate of BC patients. DLR assay verified the relationship between LINC01158 and miR-711 target binding. CCK-8 was used to detect the proliferative capacity of cells. Transwell was used to analyze cell migration and invasion ability.
resultsIn BC tissues and cell lines, LINC01158 expression was reduced and miR-711 levels were elevated. Low expression of LINC01158 resulted in a shortened overall survival of BC patients. LINC01158 binds to the miR-711 target and negatively correlates with the level of miR-711. Overexpression of LINC01158 decreased miR-711 levels and reduced BC cell proliferation, migration and invasion. In addition, Cox regression results showed that LINC01158 was an independent prognostic factor for BC.
conclusionLINC01158 may be a prognostic marker for BC. Increasing the expression level of LINC01158 could reduce the expression of miR-711, which could inhibit cell proliferation, migration and invasive behaviors, and has the potential to delay the progression of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.